Mr. Hung-Wen Chen serves as Chairman, Chief Executive Officer, and Director of Apollomics. He brings decades of leadership experience in technology, biotechnology, and pharmaceutical industries, with a proven track record in corporate transformation and strategic growth.

Mr. Chen is the founder and Chairman of Gemtek Technology Co., Ltd., which he built into one of the world’s leading manufacturers of professional wireless broadband equipment with a strong international market presence. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. In recognition of his contributions to the technology industry, he was honored with the Outstanding Alumni Award from National Tsing Hua University in 2010 and the prestigious ERSO Award in 2013.

Mr. Chen also served as Chairman and Chief Executive Officer of Polaris Pharmaceuticals, Inc., where he currently continues as Executive Director. When Polaris faced a severe financial crisis in 2019 due to uncertain clinical trial outcomes and escalating costs, Mr. Chen took decisive leadership to stabilize the company. Under his guidance, Polaris underwent a comprehensive strategic reorganization and achieved a successful turnaround, culminating in its listing on the Taiwan Stock Exchange in June 2022.

Mr. Chen holds a Bachelor’s degree in Physics and a Master’s degree in Electronics Engineering from National Tsing Hua University, Taiwan.

Mr. Yi-Kuei Chen serves as Chief Operating Officer and Director of Apollomics. He brings to the Company over two decades of leadership experience across biotechnology, venture capital, and asset management, with a strong track record in private equity investments and corporate governance.

Mr. Chen is a co-founder of Maxpro Ventures, where his expertise in asset management has led to the successful execution of more than 60 private equity investment transactions across the United States and the Asia-Pacific region. His past investments span a broad range of innovative biotechnology and pharmaceutical companies, including Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee Pharmaceuticals, HEC Pharma, and ACT Genomics Holdings.

Prior to co-founding Maxpro Ventures, Mr. Chen was Senior Director at Integral Group, where he co-led the firm’s Asian transaction process, managed its Shanghai branch, and served on the boards of portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. Earlier in his career, from 1999 to 2012, Mr. Chen held senior management positions in the investment division of Central Investment Holdings. During this period, he oversaw a series of successful investments, including Tanox and Biopure, and executed a landmark transaction in 2002 with the acquisition of SEEDNet by New Century InfoComm Tech. He also held board positions at Singfor Life Insurance Company, and CTCI Corporation.

Mr. Chen received an MBA from Syracuse University and an M.S. from the University of Minnesota.

Mr. Peter Lin brings over 20 years of diverse strategic, investment, and executive leadership experience to Apollomics. He previously served as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation (Taiwan). Before his tenure at Tanvex, Mr. Lin was Chief Financial Officer of Theragent, a start-up CDMO specializing in gene and cell therapy.

Mr. Lin’s background also includes significant expertise in investment management. As a Principal and Investment Manager at Solarium Capital, a boutique private equity fund, he executed acquisitions and equity investments across technology, food and beverage, and real estate sectors. Earlier in his career, following his MBA, he joined WesCorp as an Investment Research Manager, where he led a credit research team overseeing a $32 billion fixed-income portfolio, one of the world’s largest structured credit portfolios. His team analyzed and managed investments in U.S. and global structured finance products, including MBS, ABS, CDOs, esoteric ABS, and corporate debt securities.

Beyond his executive roles, Mr. Lin serves as a board member for companies across the biopharma, medical device, media, publishing, and real estate private equity sectors.

Mr. Lin holds a B.A. in Business Administration from the University of California, Berkeley, a Master’s degree in Information Systems from Claremont Graduate University, and an International Business Education and Research MBA from the University of Southern California (USC). He is also a Chartered Alternative Investment Analyst (CAIA) charterholder.